J&J-led coali­tion launch­es a land­mark ef­fi­ca­cy study for an HIV mo­sa­ic vac­cine

For decades now, in­ves­ti­ga­tors have been drawn to HIV vac­cine re­search — a Holy Grail in an­ti-vi­ral re­search that would have an enor­mous im­pact in a world that still sees two mil­lion new in­fec­tions every year.

Now J&J is step­ping for­ward and spear­head­ing the first ef­fi­ca­cy study — HVTN 705/HPX2008, al­so known as “Im­boko­do” — of a new, so-called mo­sa­ic vac­cine that is en­rolling 2,600 African women to check on its abil­i­ty to quell the spread of the lethal virus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER